471A Stock Chart & Stats
€0.34
-€0.02(-5.92%)
At close: 4:00 PM EDT
€0.34
-€0.02(-5.92%)
Day’s Range― - ―
52-Week Range€0.24 - €1.01
Previous CloseN/A
Volume0.00
Average Volume (3M)1.03K
Market Cap
€33.05M
Enterprise Value€12.22
Total Cash (Recent Filing)€57.42M
Total Debt (Recent Filing)€11.30M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding98,087,425
10 Day Avg. Volume0
30 Day Avg. Volume1,026
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.59Price Target Upside661.52% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exclusive Global Rights To EfzofitimodaTyr now controls efzofitimod globally across interstitial lung disease indications, giving it unified authority over development, regulatory strategy and commercialization. This removes partner-related division of control and preserves long-term optionality for the lead asset, although execution and funding remain important.
Pipeline Advancing Toward Phase 3Progress toward a Phase 3 sarcoidosis study indicates the company is advancing its lead therapeutic beyond earlier-stage development. A later-stage trial can create a clearer path toward potential regulatory evidence and commercial development, supporting pipeline durability if execution is successful.
Modest LeverageRelatively modest leverage limits the immediate burden from debt service and preserves more financial flexibility than a highly indebted balance sheet would provide. This is a durable structural advantage for a clinical-stage company, even though ongoing losses continue to erode assets and equity.
Bears Say
Minimal And Volatile Revenue With Deep LossesThe company has not established durable operating revenue or profitability, leaving its financial profile dependent on advancing clinical programs rather than a self-funding commercial base. Persistent losses reduce resilience and make future earnings power highly contingent on successful development and eventual product traction.
Persistent Cash Burn And Funding DependenceSustained negative operating and free cash flow means aTyr cannot currently fund its activities from operations. Continued cash burn increases dependence on external financing, which can constrain development choices and create recurring pressure to secure capital before advancing the pipeline.
Nasdaq Compliance And Clinical Execution RiskThe extended Nasdaq bid-price deficiency creates an ongoing listing and potential reverse-split issue that can distract management and complicate financing. Separately, the prior Phase 2 primary-endpoint miss raises uncertainty about the evidence base and execution risk for the planned Phase 3 program.
aTyr Pharma News
471A FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was €0.24 and its highest was €1.01 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is €33.05M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Aug 07, 2026. The company reported -€0.095 earnings per share for the quarter, beating the consensus estimate of -€0.105 by €0.01.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.09.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 98,087,425 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -€0.095 in its last earnings report, beating expectations of -€0.105. Following the earnings report the stock price went up 45.21%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in DE:471A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aTyr Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.59 (661.52% Upside)
€2.59 (661.52% Upside)
Blogger Sentiment
Neutral
DE:471A Sentiment 50%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
471A Stock 12 Month Forecast
Average Price Target
€2.59
▲(661.52% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―